)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
AlzeCure Pharma
AlzeCure Pharma (ALZCUR) investor relations material
AlzeCure Pharma Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary5 May, 2026
Executive summary
Focused on advancing clinical programs for Alzheimer's and pain, with key progress in NeuroRestore ACD856 and Painless ACD440 projects.
Received a €2.5 million grant from the European Innovation Council for Phase IIa trial in Alzheimer's with ACD856.
Orphan drug designation for ACD440 granted by EMA in February 2026, adding to prior US designation.
Presented new preclinical data at major international conferences, supporting both cognitive and pain indications.
Financial highlights
Net sales for Q1 2026 were SEK 0 thousand, unchanged from the prior year.
Operating loss increased to SEK -21,782 thousand from SEK -10,191 thousand year-over-year.
Earnings per share, basic, was SEK -0.19 compared to SEK -0.11 in Q1 2025.
Cash flow from operating activities was SEK -17,089 thousand, down from SEK -10,416 thousand.
Cash and cash equivalents at period end were SEK 32,967 thousand, up from SEK 20,819 thousand.
Outlook and guidance
Phase IIa clinical trial for NeuroRestore ACD856 in Alzheimer's expected to begin later in 2026.
Preparations ongoing for registrational study in pain (ACD440) and for advancing Alzstatin ACD680 and TrkA-NAM ACD137 to clinical trials.
Continued focus on business development and potential out-licensing agreements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AlzeCure Pharma
- Secured major grant, achieved key regulatory milestones, and strengthened financial position.ALZCUR
Q4 202526 Feb 2026 - ACD440 gel delivers targeted, effective neuropathic pain relief with strong safety and market potential.ALZCURStudy Update19 Jan 2026
- ACD 440 advances as a first-in-class orphan drug for erythromelalgia, targeting a $2.6B market.ALZCURStatus Update23 Nov 2025
- Oversubscribed rights issue and FDA orphan status drive R&D progress despite ongoing losses.ALZCURQ3 202511 Nov 2025
- Oversubscribed rights issue and key regulatory milestones boost funding and clinical progress.ALZCURQ2 202526 Aug 2025
- Strong R&D progress and capital raises, but financing risk remains high for AlzeCure.ALZCURQ3 202413 Jun 2025
- Q2 2024 saw R&D progress, new funding, and pipeline advances, but financing risk persists.ALZCURQ2 202413 Jun 2025
- Q1 2025 saw a €2.5M EIC grant, pipeline advances, and continued financial challenges.ALZCURQ1 20255 Jun 2025
- Advanced Alzheimer's and pain pipeline, secured EIC grant, but faces high financing risk.ALZCURQ4 20245 Jun 2025
Next AlzeCure Pharma earnings date
Q2 202626 Aug, 2026
AlzeCure Pharma
Next AlzeCure Pharma earnings date
Q2 202626 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage